Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

Therapeutic Advantage of Targeting PRMT5 in Combination with Chemotherapies or EGFR/HER2 Inhibitors in Triple-Negative Breast Cancers

Rayan Dakroub,1,2 Solène Huard,1 Yara Hajj-Younes,1 Samyuktha Suresh,1 Bassam Badran,2 Hussein Fayyad-Kazan,2 Thierry Dubois1 1Breast Cancer Biology Group, Translational Research Department, Institut Curie-PSL Research University, Paris, 75005, France; 2Laboratory of Cancer Biology and Molecular Imm...

Full description

Bibliographic Details
Main Authors: Dakroub R, Huard S, Hajj-Younes Y, Suresh S, Badran B, Fayyad-Kazan H, Dubois T
Format: Article
Language:English
Published: Dove Medical Press 2023-11-01
Series:Breast Cancer: Targets and Therapy
Subjects:
tnbc
erlotinib
neratinib
cisplatin
drug combination
Online Access:https://www.dovepress.com/therapeutic-advantage-of-targeting-prmt5-in-combination-with-chemother-peer-reviewed-fulltext-article-BCTT

Internet

https://www.dovepress.com/therapeutic-advantage-of-targeting-prmt5-in-combination-with-chemother-peer-reviewed-fulltext-article-BCTT

Similar Items